嵌合抗原受体 T (CAR-T) 细胞疗法彻底改变了血液恶性肿瘤的治疗方法，明显改善了患者的治疗结果和预后。然而，它的应用带来了新的挑战，例如安全问题、脱靶毒性和巨大的成本。自然杀伤 (NK) 细胞是先天免疫系统的重要组成部分，能够消除肿瘤细胞，而无需事先暴露于特定抗原或预激活。这种固有的优势弥补了 T 细胞的局限性，使 CAR-NK 细胞疗法成为血液肿瘤免疫治疗的一个有前途的途径。近年来，临床前和临床研究已获得初步证据支持CAR-NK细胞治疗血液恶性肿瘤的安全性和有效性，为免疫治疗的未来发展铺平了道路。本综述旨在简要讨论 CAR-NK 细胞疗法的特点、重大治疗进展和潜在挑战。版权所有 © 2024 Yang、Yang、Liu、Wang、Yang 和 He。

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, demonstrably improving patient outcomes and prognosis. However, its application has introduced new challenges, such as safety concerns, off-target toxicities, and significant costs. Natural killer (NK) cells are crucial components of the innate immune system, capable of eliminating tumor cells without prior exposure to specific antigens or pre-activation. This inherent advantage complements the limitations of T cells, making CAR-NK cell therapy a promising avenue for hematological tumor immunotherapy. In recent years, preclinical and clinical studies have yielded preliminary evidence supporting the safety and efficacy of CAR-NK cell therapy in hematological malignancies, paving the way for future advancements in immunotherapy. This review aims to succinctly discuss the characteristics, significant therapeutic progress, and potential challenges associated with CAR-NK cell therapy.Copyright © 2024 Yang, Yang, Liu, Wang, Yang and He.